BI-764532 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Neuroendocrine Cancer. According to GlobalData, Phase I drugs for Neuroendocrine Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BI-764532’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BI-764532 overview

OBT-620 is under development for the treatment of delta-like ligand 3 (DLL3) positive small-cell lung carcinoma (SCLC), extra-pulmonary neuroendocrine carcinoma (epNEC), large cells neuroendocrine lung carcinoma (LCNEC), glioma and other neuroendocrine carcinomas (NEC). It is administered by intravenous route. The drug candidate is a Bi-specific T-cell engager (BiTE) monoclonal antibody that acts by targeting CD3 and DLL3. The drug candidate is developed based on the oxford genome anatomy project (OGAP) technology. 

Boehringer Ingelheim International overview

Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for swine, ruminant, poultry, horses and pets among others. Boehringer is headquartered in Ingelheim, Rheinland-Pfalz, Germany.

For a complete picture of BI-764532’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.